SSRI and Gastritis Management
Continue the SSRI in patients with active gastritis, but add gastroprotection with a proton pump inhibitor (PPI) if the patient has additional risk factors for upper GI bleeding, particularly if they are over 50 years old or taking concurrent NSAIDs, aspirin, or anticoagulants.
Risk Assessment
SSRIs increase the risk of upper gastrointestinal bleeding by approximately 1.5 to 2-fold 1, 2. This occurs through impaired platelet aggregation due to serotonin depletion in platelets. The absolute risk remains modest—in low-risk populations, the number needed to harm is 3,177, while in high-risk populations it drops to 881 1.
Key risk factors that amplify bleeding risk:
- Age >50 years 3
- Concurrent NSAID use (increases risk 4.25-fold) 1
- Concurrent aspirin or anticoagulant therapy 4
- History of previous upper GI bleeding 4
- Active H. pylori infection (increases risk 2.73-fold in SSRI users) 5
Management Algorithm
Step 1: Assess bleeding risk
- If patient has ≥1 high-risk factor listed above → Add PPI gastroprotection
- If patient is low-risk (no risk factors, age <50) → Continue SSRI without PPI
Step 2: If PPI is indicated
- Start standard-dose PPI (e.g., omeprazole 20mg daily, pantoprazole 40mg daily)
- PPIs significantly reduce SSRI-associated GI bleeding risk 2
- Do not discontinue the SSRI unless there is active bleeding requiring hospitalization
Step 3: Consider H. pylori testing and eradication
- Test for H. pylori in patients with gastritis on SSRIs
- Eradicate if positive, as this substantially reduces bleeding risk 5
- Note: Even after H. pylori eradication, SSRIs still carry increased bleeding risk, particularly in older patients 3
When to Continue vs. Discontinue SSRI
Continue SSRI if:
- Patient has concurrent mood disorder requiring treatment 6
- Gastritis is mild-moderate without active bleeding
- Risk factors can be mitigated with PPI
Consider discontinuation only if:
- Active upper GI bleeding requiring hospitalization
- Patient develops severe gastritis with ulceration despite PPI
- Alternative antidepressant options exist (though note: tricyclic antidepressants may worsen constipation but have less bleeding risk)
Important Caveats
The 2022 AGA guidelines on PPI de-prescribing emphasize that patients at high risk for upper GI bleeding should not have their PPIs discontinued 4. SSRI use combined with other risk factors qualifies patients as high-risk.
Avoid the pitfall of stopping an effective SSRI unnecessarily. For patients with IBS and concurrent mood disorders, SSRIs at therapeutic doses are actually preferred over low-dose tricyclics because they address both GI symptoms and psychological symptoms simultaneously 6. The gastroprotective benefit of PPIs far outweighs concerns about long-term PPI use in this context 4.
If NSAIDs are being used concurrently, strongly consider discontinuing the NSAID rather than the SSRI, as the combination increases bleeding risk to 4.25-fold 1, 7. If NSAIDs cannot be stopped, PPI co-therapy is mandatory 4.